GSK3B and chronic kidney disease: Indeed, targeting GSK3β via genetic KO or pharmacological inhibitors can mitigate kidney injury in CKD by reducing cell death, inflammation, and fibrosis, thereby improving outcomes in preclinical models [25–27].